Clinical Trial Update: Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. [Phase 3]

View source ↗

Summary

Phase 3 trial update showing results of canakinumab for acute gout flares and prevention of future flares in NSAID/colchicine-intolerant patients, with a 12-wee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Gout | Phase 3 | Status: COMPLETED | Results posted: 2011-12-26